Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
about
Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patientsAngiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients.Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
P2860
Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Development and validation of ...... th bevacizumab and irinotecan.
@en
type
label
Development and validation of ...... th bevacizumab and irinotecan.
@en
prefLabel
Development and validation of ...... th bevacizumab and irinotecan.
@en
P2093
P2860
P50
P1433
P1476
Development and validation of ...... th bevacizumab and irinotecan.
@en
P2093
Anders Toft
Hans Skovgaard Poulsen
Helle Broholm
Ib Jarle Christensen
Kirsten Grunnet
Michael Kosteljanetz
Thomas Urup
Vibeke Andrée Larsen
P2860
P304
P356
10.3109/0284186X.2015.1114679
P577
2016-02-01T00:00:00Z